IRS Tax Credit for Orphan Drug Development

[James Love <love@tap.org>]

  Based upon data we received today, the entire pharmaceutical industry only
  received $20.3 million under the orphan drug tax credit for 1993.  Since
  this credit is earned by spending money on R&D for orphan drugs (on
  clinical trials?), it is remarkable in that the number is so small. 
  Unless the pharmaceutical industry hasn't learned how to minimize its tax
  liability, by taking available credits, it would seem that they aren't
  spending very much on Orphan drug development. jamie
  
  ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
  James Love / love@tap.org / P.O. Box 19367, Washington, DC 20036
  Voice: 202/387-8030; Fax 202/234-5176
  Center for Study of Responsive Law
     Consumer Project on Technology; http://www.essential.org/cpt
     Taxpayer Assets Project; http://www.tap.org
  ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~